Clinical Trial

Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC)

Name: Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC) — clinical trial record (NCT06975644)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting

View on ClinicalTrials.gov →

Summary

Evaluating Bemotuzumab to improve the efficacy of neoadjuvant chemotherapy for Triple-Negative Breast Cancer (TNBC)

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-05-09.

Trial Details

NCT Number	NCT06975644
Lead Sponsor	Zhejiang Provincial People's Hospital
Conditions	Triple-Negative Breast Cancer (TNBC), Neoadjuvant Chemotherapy, Chemotherapy Effects
Enrollment	55 participants
Start Date	2025-09-01
Primary Completion	2026-09-01 (estimated)
Study Completion	2026-12-31 (estimated)
Updated on ClinicalTrials.gov	2025-05-22